A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa

New England Journal of Medicine

Volumn 370, Issue 1, 2014, Pages 41-53

  Bwakura Dangarembizi, Mutsawashe ^a   Kendall, Lindsay ^b   Bakeera Kitaka, Sabrina ^d   Nahirya Ntege, Patricia ^f   Keishanyu, Rosette ^e   Nathoo, Kusum ^a   Spyer, Moira J ^b   Kekitiinwa, Adeodata ^d   Lutaakome, Joseph ^f   Mhute, Tawanda ^a   Kasirye, Philip ^d   Munderi, Paula ^f   Musiime, Victor ^e   Gibb, Diana M ^b   Walker, A Sarah ^b   Prendergast, Andrew J ^b,c  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d MULAGO HOSPITAL   (Uganda)

^e JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^f UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; ZIDOVUDINE; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT;

ADOLESCENT; ADVERSE OUTCOME; AFRICA SOUTH OF THE SAHARA; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE PERCENTAGE; CHILD; CHILD HEALTH CARE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA; MALE; MENINGITIS; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEPSIS; SEPTICEMIA; TREATMENT DURATION; TREATMENT OUTCOME; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; HIV INFECTIONS; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL; UGANDA; ZIMBABWE;

ADOLESCENT; ANTI-INFECTIVE AGENTS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALARIA; MALE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UGANDA; WITHHOLDING TREATMENT; ZIMBABWE;

EID: 84892170982     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1214901     Document Type: Article

References (40)

1. Anglaret X, Chêne G, Attia A., et al Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999;353:1463-8.
2. Badri M, Ehrlich R, Wood R., Maartens G. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001;15:1143-8.
3. Grimwade K, Sturm AW, Nunn A.J., Mbatha D., Zungu D, Gilks CF Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005;19:163-8.
4. Mermin J, Lule J, Ekwaru J.P., et al Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004;364:1428-34.
5. Nunn AJ, Mwaba P, Chintu C., Mwinga A, Darbyshire JH, Zumla A. Role of cotrimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 2008;337:a257.
6. Wiktor SZ, Sassan-Morokro M, Grant A.D., et al Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999;353:1469-75. [Erratum, Lancet 1999;353:2078.]
7. Chintu C, Bhat GJ, Walker A.S., et al Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004;364:1865-71.
8. Mulenga V, Ford D, Walker A.S., et al Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 2007; 21:77-84.
9. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008;8:477-89. [Erratum, Lancet Infect Dis 2009;9:736.]
10. Antiretroviral therapy for HIV infection in infants and children: towards universal access - recommendations for a public health approach. Geneva: World Health Organization, 2010 (http://www.who.int/hiv/pub/paediatric/infants2010/en/ index.html).
11. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-limited settings: recommendations for a public health approach. Geneva: World Health Organization, 2006 (http://www.who.int/hiv/pub/plhiv/ctx/en/).
12. Urschel S, Ramos J, Mellado M., et al Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS 2005;19:2103-8.
13. Nachman S, Gona P, Dankner W., et al The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005;115(4):e488-e494.
14. Suthar AB, Granich R, Mermin J., Van Rie A. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and metaanalysis. Bull World Health Organ 2012;90:128C-138C.
15. Walker AS, Ford D, Gilks C.F., et al Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010;375:1278-86.
16. ARROW Trial Team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013;381:1391-403.
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH tripartite guideline: clinical safety data management: definitions and standards for expedited reporting. 1994 (http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E2A/Step4/E2A-Guideline.pdf).
18. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization, 2006 (http://www.who.int/hiv/pub/guidelines/ hivstaging/en/index.html).
19. Peto R, Pike MC, Armitage P, et al Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
20. Royston P, Parmar MK Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002;21:2175-97.
21. Gasasira AF, Kamya MR, Ochong E.O., et al Effect of trimethoprim-sulpha- methoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J 2010;9:177.
22. Kamya MR, Gasasira AF, Achan J, et al Effects of trimethoprim- sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 2007;21:2059-66.
23. Mermin J, Ekwaru JP, Liechty C.A., et al Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticidetreated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367:1256-61.
24. Campbell JD, Moore D, Degerman R., et al HIV-infected Ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis 2012;54:1204-11.
25. Hamer DH, Gill CJ Balancing individual benefit against public health risk: the impact of cotrimoxazole prophylaxis in HIV-infected patients on antimicrobial resistance. Am J Trop Med Hyg 2008; 79:299-300.
26. Hamel MJ, Greene C, Chiller T., et al Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg 2008;79:320-30.
27. Malamba SS, Mermin J, Reingold A., et al Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg 2006;75:375-80.
28. Thera MA, Sehdev PS, Coulibaly D, et al Impact of trimethoprim- sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005;192:1823-9.
29. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization, 2010 (http://www.who.int/malaria/publications/atoz/9789241547925/ en/index.html).
30. Anglaret X, Minga A, Gabillard D., et al AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012;54:714-23.
31. Anglaret X, Toure S, Ouassa T., Dabis F, N'Dri-Yoman T. Thresholds of CD4 cells for initiating trimethoprim-sulfamethoxazole prophylaxis in west Africa. AIDS 2000;14:2628-9.
32. Corbett EL, Churchyard GJ, Charalambos S, et al Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34:1251-8.
33. Gilks CF, Ojoo SA, Ojoo J.C., et al Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996;347:718-23.
34. Forgacs P, Wengenack NL, Hall L, Zimmerman S.K., Silverman ML, Roberts GD Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2009;53:4789-93.
35. Chintu C, Mudenda V, Lucas S., et al Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002; 360:985-90.
36. Gibb DM, Newberry A, Klein N., de Rossi A, Grosch-Woerner I, Babiker A. Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet 2000;355:1331-2.
37. Prendergast A, Walker AS, Mulenga V, Chintu C., Gibb DM Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis. Clin Infect Dis 2011;52:953-6.
38. Gsponer T, Weigel R, Davies M.A., et al Variability of growth in children starting antiretroviral treatment in southern Africa. Pediatrics 2012;130(4):e966-e977.
39. Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A., Spengler U, Sauerbruch T. Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels of tumour necrosis factoralpha, interleukin-6 and their soluble receptors. Br J Haematol 1997;96:235-9.
40. Date AA, Vitoria M, Granich R., Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ 2010;88: 253-9.